Company has $66.4M in cash or $5.5 per share with almost no liabilities. Company is continuing with its projects and as biopharmaceutical company has huge potential. They have resources to continue with the development until completion. Looks like on friday it was overreaction. right now traders are trying to buy shares from weak hands (still exist) at atractive prices, but soon more and more investors will understand that company worth mucu more than $10 per share.
We bought today at $9 15/16 and $10 and willing to buy more. Book value is $5.6 per share. With the cash they have they can continue with their projects and even acquire other bio-tech companies that have not sufficient cash to follow on. Very few companies are traded in a value that is less than 2*book value.